BRPI0415833A - derivados de triaza-espiropiperidina para uso como inibidores de glyt-1 no tratamento de distúrbios neurológicos e neuropsiquiátricos - Google Patents

derivados de triaza-espiropiperidina para uso como inibidores de glyt-1 no tratamento de distúrbios neurológicos e neuropsiquiátricos

Info

Publication number
BRPI0415833A
BRPI0415833A BRPI0415833-4A BRPI0415833A BRPI0415833A BR PI0415833 A BRPI0415833 A BR PI0415833A BR PI0415833 A BRPI0415833 A BR PI0415833A BR PI0415833 A BRPI0415833 A BR PI0415833A
Authority
BR
Brazil
Prior art keywords
lower alkyl
hydrogen
treatment
trifluoromethyl
halogen
Prior art date
Application number
BRPI0415833-4A
Other languages
English (en)
Inventor
Simona Maria Ceccarelli
Emmanuel Pinard
Henri Stalder
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0415833A publication Critical patent/BRPI0415833A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS DE TRIAZA-ESPIROPIPERIDINA PARA USO COMO INIBIDORES DE GLYT-1 NO TRATAMENTO DE DISTúRBIOS NEUROLóGICOS E NEUROPSIQUIáTRICOS". A invenção refere-se aos compostos da fórmula geral em que A-Aé -CH~ 2~-CH~ 2~-, -CH~ 2~-CH~ 2~-CH~ 2~-, -CH~ 2~-O- ou -0-CH~ 2~-; X é hidrogênio ou hidróxi; R¬ 1¬ é arila ou heteroarila, substituída ou não substituída por um ou mais substituintes, selecionados dentre o grupo consistindo de alquila inferior, alcóxi inferior, halogênio ou trifluorometila; R¬ 2¬ é arila ou heteroarila, substituída ou não substituída por um ou mais substituintes, selecionados dentre o grupo consistindo de alquila inferior, alcóxi inferior, halogênio ou trifluorometila, ou é alquila inferior, -(CH~ 2~)~ n~-Cicloalquila, -(CH~ 2~)~ n~-CF~ 3~, -(CH~ 2~)~ p~O-alquila inferior, -(CH~ 2~)~ 1,2~-fenila, opcionalmente substituída por halogênio, alquila inferior, alcóxi inferior ou trifluorometila, ou é -(CH~ 2~)~ p~-NR<39>R<39><39>, em que R<39> e R<39><39> formam juntos com o N-átomo um anel heterocíclico, selecionado dentre o grupo consistindo de piperidina, morfolina, tiomorfolina ou 1,1-dioxo-tiomorfolina; R¬ 3¬, R¬ 4¬ são independentemente um de cada outro hidrogênio, alquila inferior, fenila ou benzila; R¬ 5¬ é hidrogênio, alquila inferior ou benzila; R¬ 6¬ é hidrogênio ou alquila inferior; n é 0,1 ou 2; e p é 2 ou 3; e aos sais de adição de ácido farmaceuticamente aceitáveis dos mesmos para o tratamento de psicoses, dor, disfunção neurodegenerativa em memória e aprendizagem, esquizofrenia, demência e outras doenças em que os processos cognitivos são prejudicados como distúrbios do déficit de atenção ou mal de Alzheimer.
BRPI0415833-4A 2003-10-23 2004-10-14 derivados de triaza-espiropiperidina para uso como inibidores de glyt-1 no tratamento de distúrbios neurológicos e neuropsiquiátricos BRPI0415833A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03024415 2003-10-23
PCT/EP2004/011552 WO2005040166A1 (en) 2003-10-23 2004-10-14 Triaza-spiropiperidine derivatives for use as glyt-1 inhibitors in the treatment of neurological and neuropsychiatric disorders

Publications (1)

Publication Number Publication Date
BRPI0415833A true BRPI0415833A (pt) 2007-01-02

Family

ID=34486099

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415833-4A BRPI0415833A (pt) 2003-10-23 2004-10-14 derivados de triaza-espiropiperidina para uso como inibidores de glyt-1 no tratamento de distúrbios neurológicos e neuropsiquiátricos

Country Status (19)

Country Link
US (1) US7189850B2 (pt)
EP (1) EP1678177B1 (pt)
JP (1) JP4490434B2 (pt)
KR (1) KR100798161B1 (pt)
CN (1) CN100467468C (pt)
AR (1) AR046186A1 (pt)
AU (1) AU2004283843B2 (pt)
BR (1) BRPI0415833A (pt)
CA (1) CA2543308C (pt)
CO (1) CO5690643A2 (pt)
DE (1) DE602004010419T2 (pt)
ES (1) ES2297502T3 (pt)
IL (1) IL174734A (pt)
MX (1) MXPA06004305A (pt)
NO (1) NO20061419L (pt)
RU (1) RU2006117368A (pt)
TW (1) TW200526662A (pt)
WO (1) WO2005040166A1 (pt)
ZA (1) ZA200603221B (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5266042B2 (ja) * 2005-04-11 2013-08-21 エール ユニヴァーシティ 統合失調症前駆症の治療方法
DE102005038141A1 (de) * 2005-08-12 2007-02-15 Grünenthal GmbH Substituierte 8-(3-Aminopropyl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-on-Derivate
MX2008011216A (es) 2006-03-08 2008-09-11 Hoffmann La Roche 1,5-dihidro-imidazol-2-onas 4-amino-1,5-substituidas.
JP2009530247A (ja) * 2006-03-16 2009-08-27 グラクソ グループ リミテッド Ｎ−フェニル−２−オキソ−１，４−ジアザスピロ［４．５］デカ−３−エン−１−イルアセトアミド誘導体およびグリシン輸送体阻害剤としてのそれらの使用
GB0607398D0 (en) * 2006-04-12 2006-05-24 Glaxo Group Ltd Compounds
CN101472924A (zh) * 2006-06-20 2009-07-01 惠氏公司 Kv1.5钾通道抑制剂
US20100113545A1 (en) * 2007-02-01 2010-05-06 Steven Coulton Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
WO2008092874A1 (en) * 2007-02-01 2008-08-07 Glaxo Group Limited Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
US20100105713A1 (en) * 2007-02-01 2010-04-29 Glaxo Group Limited GLYT1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders
EP2121624A1 (en) * 2007-02-01 2009-11-25 Glaxo Group Limited Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
GB0701985D0 (en) * 2007-02-01 2007-03-14 Glaxo Group Ltd Compounds
GB0701955D0 (en) * 2007-02-01 2007-03-14 Glaxo Group Ltd Compounds
WO2008092877A2 (en) * 2007-02-01 2008-08-07 Glaxo Group Limited 8-oxa-1, 4-diazaspiro [4,5] dec-3-en-1-yl and 1,4, 8-triazaspiro [4,5] dec- 3-en-1-yl acetamides as glyti transporter inhibitors in treatment of neurological and neuropsychiatric disorders
AU2008259841B2 (en) 2007-05-31 2015-02-05 Sunovion Pharmaceuticals Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
CA2691704A1 (en) 2007-07-03 2009-01-08 F. Hoffmann-La Roche Ag 4-imidazolines and their use as antidepressants
MX2009014235A (es) 2007-08-22 2010-04-27 Abbott Gmbh & Co Kg 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso.
WO2009034062A1 (en) * 2007-09-11 2009-03-19 Glaxo Group Limited Compounds which inhibit the glycine transporter and uses thereof in medicine
US20090077077A1 (en) * 2007-09-18 2009-03-19 Gerhard Geldenbott Optimal selection of MSAG address for valid civic/postal address
US7981904B2 (en) * 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
EP2527328A1 (en) 2008-04-01 2012-11-28 Abbott GmbH & Co. KG Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
SG173116A1 (en) * 2009-01-27 2011-08-29 Hoffmann La Roche Aroylamino - and heteroaroylamino-substituted piperidines as glyt-1 inhibitors
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
MX338327B (es) 2010-10-25 2016-04-12 G1 Therapeutics Inc Inhibidores de cdk.
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8853196B2 (en) 2011-08-05 2014-10-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
CN104011028A (zh) 2011-11-18 2014-08-27 艾伯维德国有限责任两合公司 N-取代的氨基苯并环庚烯、氨基四氢化萘、氨基茚满和苯烷基胺衍生物、包含所述衍生物的药物组合物及其在治疗中的用途
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
CA2868966C (en) 2012-03-29 2021-01-26 Francis Xavier Tavares Lactam kinase inhibitors
JP2015157764A (ja) * 2012-06-14 2015-09-03 大正製薬株式会社 グリシントランスポーター阻害物質
ME03557B (me) 2013-03-15 2020-07-20 G1 Therapeutics Inc Privremena zaštiтa normalnih ćelija током hemoterapije
CA2906157C (en) 2013-03-15 2022-05-17 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
SG11201602935PA (en) 2013-10-17 2016-05-30 Abbvie Deutschland Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2015055770A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
CN106061969B (zh) 2014-01-06 2019-10-29 阿尔戈么迪克斯有限公司 Trpa1调节剂
WO2015161288A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use as anti-neoplastic and anti-proliferative agents
EP3134406A1 (en) 2014-04-24 2017-03-01 Dart Neuroscience (Cayman) Ltd Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2h-pyrazolo [4,3-c]pyridine compounds as glyt1 inhibitors
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
EP3215500A1 (en) 2014-11-05 2017-09-13 Dart NeuroScience (Cayman) Ltd. Substituted azetidinyl compounds as glyt1 inhibitors
CN108713019B (zh) 2016-03-17 2021-06-15 豪夫迈·罗氏有限公司 具有作为taar的激动剂的活性的5-乙基-4-甲基-吡唑-3-甲酰胺衍生物
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
MX2019008158A (es) 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
WO2019006393A1 (en) 2017-06-29 2019-01-03 G1 Therapeutics, Inc. Morphic forms of git38 and methods of manufacture thereof
AU2019325685B2 (en) 2018-08-24 2025-07-24 Pharmacosmos Holding A/S Improved synthesis of 1,4-diazaspiro(5.5)undecan-3-one
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0921125T1 (en) * 1997-12-05 2002-04-30 F. Hoffmann-La Roche Ag 1,3,8-Triazaspiro(4,5)decan-4-on derivatives
ATE212635T1 (de) * 1997-12-05 2002-02-15 1,3,8-triazaspiro(4,5)decan-4-on-derivate
SI1594840T1 (sl) * 2003-02-17 2006-12-31 Hoffmann La Roche Derivati piperidin-benzensulfonamida

Also Published As

Publication number Publication date
CA2543308C (en) 2012-03-06
ZA200603221B (en) 2009-04-29
MXPA06004305A (es) 2006-06-05
CO5690643A2 (es) 2006-10-31
US20050107373A1 (en) 2005-05-19
IL174734A (en) 2010-05-31
IL174734A0 (en) 2006-08-20
EP1678177A1 (en) 2006-07-12
ES2297502T3 (es) 2008-05-01
AU2004283843B2 (en) 2010-04-22
US7189850B2 (en) 2007-03-13
AU2004283843A1 (en) 2005-05-06
AR046186A1 (es) 2005-11-30
CA2543308A1 (en) 2005-05-06
CN1871238A (zh) 2006-11-29
DE602004010419T2 (de) 2008-10-09
JP2007509097A (ja) 2007-04-12
DE602004010419D1 (de) 2008-01-10
KR100798161B1 (ko) 2008-01-28
WO2005040166A1 (en) 2005-05-06
KR20060076317A (ko) 2006-07-04
EP1678177B1 (en) 2007-11-28
CN100467468C (zh) 2009-03-11
JP4490434B2 (ja) 2010-06-23
TW200526662A (en) 2005-08-16
NO20061419L (no) 2006-07-14
RU2006117368A (ru) 2007-12-10

Similar Documents

Publication Publication Date Title
BRPI0415833A (pt) derivados de triaza-espiropiperidina para uso como inibidores de glyt-1 no tratamento de distúrbios neurológicos e neuropsiquiátricos
BRPI0407543A (pt) derivados de piperidina-benzenossulfonamida
BR0306208A (pt) Compostos de dibenzilamina e seu uso farmacêutico
EA200501516A1 (ru) Производные 2,3,6-тризамещённого-4-пиримидона
BRPI0112475B8 (pt) n-óxido de derivados 4-fenil-piridina como antagonista de receptor nk1, seu medicamento, seu processo de preparação e seus usos
BRPI0213393B8 (pt) derivados de éter alquílico, ou um de seus sais, processo para produzir um derivado de éter alquílico, derivado de alquil-amida, ou um de seus sais, e, composição farmacêutica
BRPI0413536B8 (pt) derivados de 1-benzoil-piperazina, seu uso e medicamento que os compreende
NO20073667L (no) [4-(heteroaryl) piperazin-1-yl]-(2,5-substituert-fenyl)metanonderivater som glycintransportor 1(GLYT-1)- inhibitorer for behandling av neurologiske og neuropsykiatriske lidelser
ATE545413T1 (de) Antagonisten des opioidrezeptors
BRPI0409110A (pt) derivados de 4-(4-heterociclilalcoxi)fenil-1-(heterociclil-carboni l)piridina e compostos relacionados como antagonistas de histamina h3 para o tratamento de doenças neurológicas tais como alzheimer
AR040278A1 (es) Ligandos del receptor de glucocorticoides para el tratamiento de trastornos metabolicos
CY1116350T1 (el) Mopφh συνκρυσταλλου «α» της [4-(3-φθορο-5-τριφθορομεθυλο-πυριδιν-2-υλο)-πιπεραζιν-1-υλο]-[5-μεθανοσουλφονυλο-2-((s)-2,2,2-τριφθορο-1-μεθυλο-αιθοξυ)-φαινυλο]-μεθανονης με μεθυλοπαραμπεν
BRPI0607600A2 (pt) derivados de 4-oxoquinazolin-3-il-benzamida para o tratamento de doenças relacionadas com citocina
DE60111464D1 (de) Azabicycloalkan-Derivate zur Verwendung als Inhibitoren der Serotonin-Wiederaufnahme und als 5HT2a Antagonisten
PE20040911A1 (es) Derivados de 3h-quinazolin-4-ona como inhibidores selectivos de la monoaminooxidasa b
ATE475640T1 (de) Antagonisten des opioidrezeptors
BR0317422A (pt) Compostos de n-(indoletil) cicloamina
EA200970596A1 (ru) Соединения с сочетанием антагонистической активности в отношении каннабиноидных рецепторов сви ингибирующей активности в отношении ацетилхолинэстеразы
NO20063597L (no) Acetylinske piperazinforbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
WO2007054444A3 (en) 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives
EP1473295A4 (en) CONDENSED BICYCLIC PYRIMIDINE DERIVATIVES
Barbay et al. Synthesis and characterization of 5, 6, 7, 8-tetrahydroquinoline C5a receptor antagonists
BRPI0414460A (pt) compostos derivados de carboxamida do tipo de amida, composição farmacêutica e respectivo uso
Alagarsamy et al. Synthesis of 4-butyl-1-substituted-4H-[1, 2, 4] triazolo [4, 3-a] quinazolin-5-ones as new class of H1-antihistaminic agents
BRPI0414597A (pt) derivados de benzofurano do tipo carbamoìla

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.